Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation.

Nguyen PL, Chen MH, Goldhaber SZ, Martin NE, Beard CJ, Dosoretz DE, Katin MJ, Ross R, Salenius SA, D'Amico AV.

Cancer. 2011 Jan 15;117(2):406-13. doi: 10.1002/cncr.25597. Epub 2010 Aug 31.

2.

Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.

Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D'Amico AV, Ennis RD.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1411-6. doi: 10.1016/j.ijrobp.2011.04.067. Epub 2011 Jun 25.

PMID:
21708431
3.

Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.

Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

JAMA. 2009 Aug 26;302(8):866-73. doi: 10.1001/jama.2009.1137.

4.

Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.

Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, Choueiri TK, D'Amico AV.

BJU Int. 2010 Oct;106(7):979-85. doi: 10.1111/j.1464-410X.2010.09273.x. Epub 2010 Mar 4.

5.

Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.

Hoffman KE, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin MJ, Ross R, D'Amico AV.

Cancer. 2010 Jun 1;116(11):2590-5. doi: 10.1002/cncr.24974.

6.

Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.

Dosoretz AM, Chen MH, Salenius SA, Ross RH, Dosoretz DE, Katin MJ, Mantz C, Nakfoor BM, D'Amico AV.

Cancer. 2010 Feb 15;116(4):837-42. doi: 10.1002/cncr.24750.

7.

Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external beam radiation therapy with and without adjuvant androgen deprivation therapy at the British Columbia Cancer Agency.

Kim J, Vaid M, Tyldesley S, Woods R, Pickles T.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):742-50. doi: 10.1016/j.ijrobp.2010.03.018. Epub 2010 Jul 12.

PMID:
20630664
8.

Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):e209-15. doi: 10.1016/j.ijrobp.2012.11.039. Epub 2013 Jan 16.

PMID:
23332383
9.

Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer.

Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL.

Brachytherapy. 2013 Sep-Oct;12(5):415-21. doi: 10.1016/j.brachy.2013.02.005. Epub 2013 May 4.

PMID:
23651926
10.

Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.

D'Amico AV, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, Chen MH.

J Clin Oncol. 2009 Aug 20;27(24):3923-8. doi: 10.1200/JCO.2008.20.3992. Epub 2009 Jul 13. Erratum in: J Clin Oncol. 2011 Apr 1;29(10):1394.

PMID:
19597029
12.

Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease.

Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH.

N Engl J Med. 2008 Jan 24;358(4):331-41. doi: 10.1056/NEJMoa071804.

13.

The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation.

Holmes DR Jr, Kim LJ, Brooks MM, Kip KE, Schaff HV, Detre KM, Frye RL; Bypass Angioplasty Revascularization Investigation (BARI) Investigators.

J Thorac Cardiovasc Surg. 2007 Jul;134(1):38-46, 46.e1.

14.

One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials.

Mercado N, Wijns W, Serruys PW, Sigwart U, Flather MD, Stables RH, O'Neill WW, Rodriguez A, Lemos PA, Hueb WA, Gersh BJ, Booth J, Boersma E.

J Thorac Cardiovasc Surg. 2005 Aug;130(2):512-9.

15.

Coronary artery revascularization and the risk of death in men with prostate cancer.

D'Amico AV, Chen MH, Dosoretz D, Katin M, Salenius S, Ross R, Goldhaber SZ.

J Urol. 2011 Sep;186(3):898-902. doi: 10.1016/j.juro.2011.04.076. Epub 2011 Jul 23.

PMID:
21788044
16.

A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.

Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A.

J Urol. 2005 Sep;174(3):882-7.

PMID:
16093980
17.

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.

Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ.

Pharmacotherapy. 2008 Dec;28(12):1511-22. doi: 10.1592/phco.28.12.1511. Review.

PMID:
19025432
18.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
19.

Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.

D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.

Cancer. 2008 Dec 15;113(12):3290-7. doi: 10.1002/cncr.23970.

20.

Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?

Stone NN, Marshall DT, Stone JJ, Cesaretti JA, Stock RG.

J Urol. 2010 Feb;183(2):634-9. doi: 10.1016/j.juro.2009.09.084. Epub 2009 Dec 16.

PMID:
20018308

Supplemental Content

Support Center